Specific exclusion criteria for participants with hepatic impair- ment included: clinically significant renal disease (estimated glomeru- lar filtration rate < 60 mL/min/1.73 m2 using the Modification of Diet in Renal Disease formula17); liver transplantation; biliary obstruc- tion and/or other causes of hepatic impairment not related to paren- chymal disorders and/or diseases; history or presence of severe hepatic encephalopathy (â‰¥ grade 3); advanced ascites, and ascites which required emptying and albumin supplementation; and oesopha- geal variceal bleeding <3 months prior to screening. Participants who used any prescription or non-prescription medi- cation which could interfere with the trial pharmacokinetic results, as judged by the investigator, were to be withdrawn. 2.2 | Trial design and treatment This was a multicentre, single-dose, parallel-group, open-label trial. 